[DOI] [PMC free article] [PubMed] [Google Scholar] 145.Mann M.C., Hemmelgarn B.R., Exner D.V., Hanley D.A., Turin T.C., Wheeler D.C., Sola D.Y., Ellis L., Ahmed S.B
For a recent phase 2 trial, French researchers gave 156 people in the early stages of Parkinsons a GLP-1 agonist (lixisenatide) or placebo every day for 1 year
That said, pen devices differ and compatibility is not universal some newer devices use ultra-fine gauges that behave differently
The research team would compare the biomarkers from Phase 2 (Tirzepatide alone) with those from Phase 3 (Tirzepatide + Lipo C)
Remove the Needle: Withdraw the needle at the same angle it was inserted, and dispose of it in a sharps container
The exact timing is different for everyone, but its a common experience, she notes